Retrospective analysis of human Equilibrative Nucleoside Transporter 1 (hENT1) expression in pancreatic cancer in patients treated with gemcitabine or fluorouracil.

Trial Profile

Retrospective analysis of human Equilibrative Nucleoside Transporter 1 (hENT1) expression in pancreatic cancer in patients treated with gemcitabine or fluorouracil.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2011

At a glance

  • Drugs Fluorouracil; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2011 Primary endpoint 'Biomarker-levels' has been met, according to a Clavis Pharma media release.
    • 24 Oct 2011 Results were reported in a Clavis Pharma media release.
    • 24 Oct 2011 Status changed from recruiting to completed, according to a Clavis Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top